75 related articles for article (PubMed ID: 17725410)
1. E1A- and E1B-Double mutant replicating adenovirus elicits enhanced oncolytic and antitumor effects.
Kim J; Kim JH; Choi KJ; Kim PH; Yun CO
Hum Gene Ther; 2007 Sep; 18(9):773-86. PubMed ID: 17725410
[TBL] [Abstract][Full Text] [Related]
2. Transthyretin-driven oncolytic adenovirus suppresses tumor growth in orthotopic and ascites models of hepatocellular carcinoma.
Hsieh JL; Lee CH; Teo ML; Lin YJ; Huang YS; Wu CL; Shiau AL
Cancer Sci; 2009 Mar; 100(3):537-45. PubMed ID: 19134007
[TBL] [Abstract][Full Text] [Related]
3. Adenovirus E1B 19-kilodalton protein modulates innate immunity through apoptotic mimicry.
Radke JR; Grigera F; Ucker DS; Cook JL
J Virol; 2014 Mar; 88(5):2658-69. PubMed ID: 24352454
[TBL] [Abstract][Full Text] [Related]
4. Systemic delivery of an oncolytic adenovirus expressing soluble transforming growth factor-β receptor II-Fc fusion protein can inhibit breast cancer bone metastasis in a mouse model.
Hu Z; Zhang Z; Guise T; Seth P
Hum Gene Ther; 2010 Nov; 21(11):1623-9. PubMed ID: 20712434
[TBL] [Abstract][Full Text] [Related]
5. Establishment of biological and pharmacokinetic assays of telomerase-specific replication-selective adenovirus.
Hashimoto Y; Watanabe Y; Shirakiya Y; Uno F; Kagawa S; Kawamura H; Nagai K; Tanaka N; Kumon H; Urata Y; Fujiwara T
Cancer Sci; 2008 Feb; 99(2):385-90. PubMed ID: 18201270
[TBL] [Abstract][Full Text] [Related]
6. E1A expression dysregulates IL-8 production and suppresses IL-6 production by lung epithelial cells.
van den Berg A; Snoek M; Jansen HM; Lutter R
Respir Res; 2005 Sep; 6(1):111. PubMed ID: 16185356
[TBL] [Abstract][Full Text] [Related]
7. Development and characterization of bovine x human hybrid cell lines that efficiently support the replication of both wild-type bovine and human adenoviruses and those with E1 deleted.
van Olphen AL; Mittal SK
J Virol; 2002 Jun; 76(12):5882-92. PubMed ID: 12021321
[TBL] [Abstract][Full Text] [Related]
8. Targeted and armed oncolytic adenovirus via chemoselective modification.
Banerjee PS; Zuniga ES; Ojima I; Carrico IS
Bioorg Med Chem Lett; 2011 Sep; 21(17):4985-8. PubMed ID: 21669527
[TBL] [Abstract][Full Text] [Related]
9. Fiber-modified hexon-chimeric oncolytic adenovirus targeting cancer associated fibroblasts inhibits tumor growth in gastric carcinoma.
Pang T; Wang X; Gao J; Chen W; Shen XJ; Nie MM; Luo T; Yin K; Fang G; Wang KX; Xue XC
Oncotarget; 2017 Sep; 8(44):76468-76478. PubMed ID: 29100326
[TBL] [Abstract][Full Text] [Related]
10. A New HEK293 Cell with CR2 Region of E1A Gene Deletion Prevents the Emergence of Replication-Competent Adenovirus.
Lian X; Zhao X; Zhong J; Zhang C; Chu Y; Wang Y; Lu S; Wang Z
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136259
[TBL] [Abstract][Full Text] [Related]
11. Relaxin-expressing oncolytic adenovirus induces remodeling of physical and immunological aspects of cold tumor to potentiate PD-1 blockade.
Jung BK; Ko HY; Kang H; Hong J; Ahn HM; Na Y; Kim H; Kim JS; Yun CO
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32753544
[TBL] [Abstract][Full Text] [Related]
12. Developing Oncolytic Viruses for the Treatment of Cervical Cancer.
Kalafati E; Drakopoulou E; Anagnou NP; Pappa KI
Cells; 2023 Jul; 12(14):. PubMed ID: 37508503
[TBL] [Abstract][Full Text] [Related]
13. CRISPR-Cas12a with an oAd Induces Precise and Cancer-Specific Genomic Reprogramming of EGFR and Efficient Tumor Regression.
Yoon AR; Jung BK; Choi E; Chung E; Hong J; Kim JS; Koo T; Yun CO
Mol Ther; 2020 Oct; 28(10):2286-2296. PubMed ID: 32682455
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic adenovirus coexpressing interleukin-12 and decorin overcomes Treg-mediated immunosuppression inducing potent antitumor effects in a weakly immunogenic tumor model.
Oh E; Choi IK; Hong J; Yun CO
Oncotarget; 2017 Jan; 8(3):4730-4746. PubMed ID: 28002796
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic adenovirus coexpressing interleukin-12 and shVEGF restores antitumor immune function and enhances antitumor efficacy.
Ahn HM; Hong J; Yun CO
Oncotarget; 2016 Dec; 7(51):84965-84980. PubMed ID: 27821803
[TBL] [Abstract][Full Text] [Related]
16. Evolving lessons on nanomaterial-coated viral vectors for local and systemic gene therapy.
Kasala D; Yoon AR; Hong J; Kim SW; Yun CO
Nanomedicine (Lond); 2016 Jul; 11(13):1689-713. PubMed ID: 27348247
[TBL] [Abstract][Full Text] [Related]
17. shRNA-armed conditionally replicative adenoviruses: a promising approach for cancer therapy.
Zhang J; Ding M; Xu K; Mao L; Zheng J
Oncotarget; 2016 May; 7(20):29824-34. PubMed ID: 26980708
[TBL] [Abstract][Full Text] [Related]
18. Hepatoma targeting peptide conjugated bio-reducible polymer complexed with oncolytic adenovirus for cancer gene therapy.
Choi JW; Kim HA; Nam K; Na Y; Yun CO; Kim S
J Control Release; 2015 Dec; 220(Pt B):691-703. PubMed ID: 26437261
[TBL] [Abstract][Full Text] [Related]
19. A vesicular stomatitis virus glycoprotein epitope-incorporated oncolytic adenovirus overcomes CAR-dependency and shows markedly enhanced cancer cell killing and suppression of tumor growth.
Yoon AR; Hong J; Yun CO
Oncotarget; 2015 Oct; 6(33):34875-91. PubMed ID: 26430798
[TBL] [Abstract][Full Text] [Related]
20. Adenovirus expressing dual c-Met-specific shRNA exhibits potent antitumor effect through autophagic cell death accompanied by senescence-like phenotypes in glioblastoma cells.
Lee JS; Oh E; Yoo JY; Choi KS; Yoon MJ; Yun CO
Oncotarget; 2015 Feb; 6(6):4051-65. PubMed ID: 25726528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
